OptiNose, Inc. (OPTN): Price and Financial Metrics

OptiNose, Inc. (OPTN)

Today's Latest Price: $3.77 USD

0.01 (-0.26%)

Updated Oct 23 6:55pm

Add OPTN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

OPTN Stock Summary

  • OPTN's went public 3.03 years ago, making it older than only 9.34% of listed US stocks we're tracking.
  • Revenue growth over the past 12 months for OptiNose Inc comes in at 153.84%, a number that bests 96.16% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for OPTN comes in at -43.67% -- higher than that of only 9.99% of stocks in our set.
  • Stocks that are quantitatively similar to OPTN, based on their financial statements, market capitalization, and price volatility, are ESTA, SIEN, PWFL, STIM, and ZIXI.
  • Visit OPTN's SEC page to see the company's official filings. To visit the company's web site, go to www.optinose.com.

OPTN Stock Price Chart Interactive Chart >

Price chart for OPTN

OPTN Price/Volume Stats

Current price $3.77 52-week high $11.66
Prev. close $3.78 52-week low $3.28
Day low $3.61 Volume 287,000
Day high $3.87 Avg. volume 410,582
50-day MA $4.25 Dividend yield N/A
200-day MA $5.24 Market Cap 173.39M

OptiNose, Inc. (OPTN) Company Bio

OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. The company was founded in 2010 and is based in Yardley, Pennsylvania.

OPTN Latest News Stream

Event/Time News Detail
Loading, please wait...

OPTN Latest Social Stream

Loading social stream, please wait...

View Full OPTN Social Stream

Latest OPTN News From Around the Web

Below are the latest news stories about OptiNose Inc that investors may wish to consider to help them evaluate OPTN as an investment opportunity.

OptiNose: Future Outlook Beyond The Coronavirus Crisis

Introduction The share price of OptiNose (OPTN) has not been performing well in 2020. Investors seemed to have lost confidence in the company and shares have suffered again after the company initiated an additional equity offering in mid-August. This might be short-sighted without having the predicted sell-side consensus of over...

Tien Duy Vo on Seeking Alpha | September 9, 2020

OptiNose EPS in-line, beats on revenue

OptiNose (OPTN): Q2 GAAP EPS of -$0.56 in-line.Revenue of $10.27M (+53.7% Y/Y) beats by $0.53M.Press Release...

Seeking Alpha | August 4, 2020

Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights

Company reports second quarter 2020 XHANCE net revenue of $10.3 million Second quarter 2020 XHANCE prescriptions increased 84% from second quarter …

Benzinga | August 4, 2020

Optinose Announces Reporting Date for Second Quarter 2020 Financial Results

YARDLEY, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat…

GlobeNewswire | July 30, 2020

Optinose names Catherine E. Owen as Director

YARDLEY, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Catherine E. Owen as a new director. Catherine currently serves as Senior Vice President, Major Markets at Bristol-Myers Squibb, overseeing commercial operations for the business in 18 countries including Japan, Germany, France, and others across Europe. She joined BMS in 2019 from Johnson & Johnson, where she served most recently as President of Janssen Immunology North America, which launched new products in Crohn’s disease and psoriasis and led the development of J&J’s biosimilars strategy. Prior to leading Immunology, she was the President of the Infectious...

Yahoo | July 29, 2020

Read More 'OPTN' Stories Here

OPTN Price Returns

1-mo 0.53%
3-mo -23.53%
6-mo -9.81%
1-year -51.10%
3-year -81.43%
5-year N/A
YTD -59.11%
2019 48.71%
2018 -67.20%
2017 N/A
2016 N/A
2015 N/A

Continue Researching OPTN

Here are a few links from around the web to help you further your research on OptiNose Inc's stock as an investment opportunity:

OptiNose Inc (OPTN) Stock Price | Nasdaq
OptiNose Inc (OPTN) Stock Quote, History and News - Yahoo Finance
OptiNose Inc (OPTN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7354 seconds.